BGI Group responds to coronavirus crisis by providing reagent kits for molecular 2019-nCoV testing by next-generation sequencing and RT-PCR- Ares Genetics to launch next-generation sequencing testing service for infection control and monitoring of 2019-nCoV evolution using
BGI Group reagents - Ares Genetics,
Curetis Group andBGI Group to collaborate in the distribution of next-generations sequencing and PCR testing kits for 2019-nCoV
2019-nCoV is a new coronavirus variant that has not been previously identified in humans but is responsible for the outbreak originating in the Chinese city of
In addition to the rapid detection kit based on RT-PCR technology, the DNBSEQ-T7 sequencing platform developed by the
In
Ares Genetics is a digital diagnostics company utilizing artificial intelligence-powered molecular diagnostics to advance the field of infectious disease testing. Ares Genetics recently launched ARESupa – Universal Pathogenome Assay for the broad identification of bacterial pathogens and the accurate prediction of antibiotic susceptibility. The ARESupa test is based on the sequencing of bacterial DNA, combined with data analysis and interpretation powered by ARESdb, Ares Genetics’ unique, proprietary reference database on genetic antimicrobial resistance markers. The first generation of ARESupa is currently offered for non-diagnostic applications in epidemiology, infection control, and outbreak analysis for customers in the public health sector and the pharmaceutical industry. A laboratory-developed test (LDT) for human diagnostic use is under development.
“The ability to rapidly test for 2019-nCoV with PCR as well as track its evolution by next-generation sequencing is key to contain this global outbreak. While Ares Genetics specializes in molecular detection of bacterial pathogens and antibiotic susceptibility prediction, we are responding to the global coronavirus health threat via our specialized molecular service laboratory and making 2019-nCoV testing broadly available in
###
About ARESupa Universal Pathogenome Assay
Information on antibiotic susceptibility of pathogens is of utmost importance for clinical practice, epidemiology and public health purposes as well as for the development of pharmaceutical products in the infectious disease sector. Ares Genetics therefore has developed a molecular Antibiotic Susceptibility Test (AST) that is marketed under the brand name ARESupa – Universal Pathogenome Assay and is capable of accurately identifying microbial pathogens as well as predicting antibiotic susceptibility via artificial intelligence-powered interpretation of high-throughput DNA sequencing data obtained by next-generation sequencing technologies.
ARESupa is based on whole-genome sequencing of bacterial strains isolated from clinical specimens, combined with data analysis and interpretation powered by ARESdb, Ares Genetics’ unique, proprietary reference database on genetic antimicrobial resistance markers. ARESdb covers genomes of about 40,000 bacterial strains and associated susceptibility data for more than 100 different antibiotics.
ARESupa already today accurately detects antibiotic susceptibility broadly across drug/pathogen combinations with prediction algorithms for further drug/pathogen combinations in development.
The test is initially offered for non-diagnostic applications in epidemiology, infection control, and outbreak analysis for customers in the public health sector and the pharmaceutical industry. A laboratory-developed test (LDT) on native patient samples for human diagnostic use in indications in which current culture-based diagnostic practice is inherently challenging is planned. Furthermore, Ares Genetics has recently entered into a multi-phase strategic partnership with an undisclosed leading global in vitro diagnostics corporation to jointly develop diagnostic solutions for infectious disease testing based on the ARESupa.
For further information and quotes, please register on the Ares Genetics cloud platform:
https://ares-genetics.cloud/
or contact
Karl-Farkas-Gasse 18
A-1030
Email: services@ares-genetics.com
About
Curetis N.V.’s (Euronext: CURE) goal is to become a leading provider of innovative solutions for molecular microbiology diagnostics designed to address the global challenge of detecting severe infectious diseases and identifying antibiotic resistances in hospitalized patients.
Curetis’ Unyvero System is a versatile, fast and highly automated molecular diagnostic platform for easy-to-use, cartridge-based solutions for the comprehensive and rapid detection of pathogens and antimicrobial resistance markers in a range of severe infectious disease indications. Results are available within hours, a process that can take days or even weeks if performed with standard diagnostic procedures, thereby facilitating improved patient outcomes, stringent antibiotic stewardship and health-economic benefits. Unyvero in vitro diagnostic (IVD) products are marketed in
Curetis’ wholly owned subsidiary
For further information, please visit www.curetis.com and www.ares-genetics.com.
About
Founded in 1999, BGI is one of the world's leading life science and genomics organizations. BGI’s mission is to use genomics to benefit mankind and to be a leader in the era of life sciences. BGI follows a genomics development model of “research, production and application”. With businesses in more than 100 countries and regions around the world, BGI has established cooperation and partnerships with thousands of different organizations across multi-disciplinary research areas including medical health, resource conservation and judicial services. At the same time, BGI provides equipment, technical support and solutions for the needs of national economies and people's livelihoods, such as precision medicine and precision health. BGI is committed to applying its genetic and technological achievements to real world settings in order to realize the dream of trans-omics for a better life.
About MGI
Founded in 2016, MGI has more than 1,000 employees, nearly half of whom are R&D personnel. MGI operates in 26 countries and regions and has established multiple research and production bases around the world. Providing real-time, comprehensive, life-long solutions, its vision is to enable effective and affordable healthcare solutions for all.
Legal Disclaimer
This document constitutes neither an offer to buy nor to subscribe securities and neither this document nor any part of it should form the basis of any investment decision in
The information contained in this press release has been carefully prepared. However,
This press release includes statements that are, or may be deemed to be, “forward-looking statements”. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms “believes”, “estimates”, “anticipates”, “expects”, “intends”, “may”, “will”, or “should”, and include statements
Curetis Group Contact Details
Max-Eyth-Str. 42
71088 Holzgerlingen,
Tel. +49 7031 49195-10
pr@curetis.com or ir@curetis.com
www.curetis.com
Karl-Farkas-Gasse 18
A-1030
Tel. +43 1 361 8880 10
contact@ares-genetics.com
www.ares-genetics.com
Curetis Group International Media & Investor Inquiries
akampion
Dr.
Managing Partners
info@akampion.com
Tel. +49 40 88 16 59 64
Tel. +49 30 23 63 27 68
Attachment
- 20200130_Ares_BGI-MGI_CoronaVirus_final_approved
2020 GlobeNewswire, Inc., source